Regulatory Strategy for Recombinant Therapeutics and Monoclonal Antibodies in India

Recombinant Therapeutics and Monoclonal antibodies (mAbs) represent the fastest-growing and highest-value segment of the global Biological Medicines market. India’s mAb market is expanding rapidly, driven by biosimilar development, originator launches, and the government’s Ayushman Bharat health coverage expansion.

For global biotech companies seeking Indian Regulatory approval for recombinant Therapeutics and mAbs, the pathway involves both CDSCO’s New Drug evaluation framework and RCGM oversight for rDNA-derived Biologicals. Navigating this dual-authority process — from pre-IND through lifecycle management — requires a precisely structured regulatory strategy.

1. Regulatory Classification

Recombinant therapeutics and mAbs are classified as ‘New Drugs’ under the NDCT Rules, 2019 when first introduced in India, regardless of global approval status. They are also subject to RCGM oversight under DBT’s biosafety framework because they are produced using recombinant DNA technology. This creates a dual oversight requirement: CDSCO for Drug safety, efficacy, and marketing authorisation; RCGM for biosafety clearance of the rDNA manufacturing process.

2. RCGM Involvement: When and Why

RCGM approval under the Department of Biotechnology is required:

1. Before initiating clinical manufacturing of a recombinant Biological in India
2. Before Importing recombinant products for clinical use in Indian patients
3. For any genetic modification to the production cell line that constitutes a new rDNA event
4. For scale-up of rDNA manufacturing processes beyond approved levels

The RCGM review assesses the production cell line (CHO, NS0, E. coli, etc.), the rDNA construct and expression system, biosafety classification, and downstream processing steps. RCGM review timelines typically add 3 to 6 months to the overall regulatory timeline.

3. The mAb Regulatory Pathway: Step by Step

Phase 1: Pre-IND Strategy and RCGM Notification

Initiate RCGM notification for the rDNA manufacturing process simultaneously with CDSCO pre-submission engagement. The RCGM submission includes the biosafety data package for the expression system, containment protocols, and manufacturing process description.

Phase 2: CDSCO Clinical Trial Application

Following RCGM clearance, Form CT-04 is filed with CDSCO for Indian Phase I/II/III studies, or a waiver application is filed if the mAb is already approved in a reference jurisdiction with sufficient Phase III data. The Subject Expert Committee (SEC) reviews the IND package including Modules 3, 4, and 5.

Phase 3: Indian Phase III or Bridging Study

For most mAbs — even globally approved ones — CDSCO requires Phase III data from Indian patients. A bridging study (typically 100-300 patients) may be sufficient for globally approved products where ethnic sensitivity analysis supports data extrapolation.

Phase 4: Marketing Authorisation Application

The MAA is submitted with the complete CTD incorporating Indian patient data. SEC conducts the final review and provides a recommendation to the DCGI. Approval timelines from MAA submission range from 12 to 24 months depending on dossier quality and product complexity.

4. Immunogenicity: A Critical Consideration

Immunogenicity is a defining safety concern for all Biological Therapeutics, and CDSCO has progressively heightened its expectations. Key requirements include:

5. Anti-Drug antibody (ADA) incidence and titre data from Clinical studies, stratified by population and treatment duration
6. Correlation analysis between ADA status and Clinical outcomes (efficacy loss, adverse events, hypersensitivity reactions)
7. Immunogenicity risk assessment under the ICH S6(R1) framework
8. Neutralising antibody data where clinically significant
9. India-specific immunogenicity data from the Indian bridging study

5. Lifecycle Management Obligations

10. Post-marketing surveillance (PMS) commitments — typically 2 years for New Biological Drugs with periodic PSURs to CDSCO
11. Manufacturing change management — CMC changes must be notified via variation applications; major changes require prior approval
12. RCGM re-notification for significant manufacturing process changes involving rDNA technology
13. PvPI compliance — ongoing ADR reporting with PVOIC oversight

6. India Bridging Strategy: Key Principles

Table 1

Conclusion

India represents a substantial and growing opportunity for recombinant Therapeutics and mAb developers. The Regulatory pathway, while multi-layered due to CDSCO and RCGM involvement, is navigable with the right strategy. A well-designed Indian clinical programme, rigorous immunogenicity monitoring, and proactive multi-authority engagement are the pillars of successful mAb approval in India.